- Home
- LGI vs MRSN Comparison
LGI vs MRSN Comparison
Compare LGI & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGI
- MRSN
- Stock Information
- Founded
- LGI 2004
- MRSN 2001
- Country
- LGI United States
- MRSN United States
- Employees
- LGI N/A
- MRSN N/A
- Industry
- LGI
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LGI
- MRSN Health Care
- Exchange
- LGI Nasdaq
- MRSN Nasdaq
- Market Cap
- LGI 217.8M
- MRSN 252.0M
- IPO Year
- LGI N/A
- MRSN 2017
- Fundamental
- Price
- LGI $16.69
- MRSN $2.04
- Analyst Decision
- LGI
- MRSN Buy
- Analyst Count
- LGI 0
- MRSN 6
- Target Price
- LGI N/A
- MRSN $6.00
- AVG Volume (30 Days)
- LGI 41.1K
- MRSN 1.3M
- Earning Date
- LGI 01-01-0001
- MRSN 11-13-2024
- Dividend Yield
- LGI 7.10%
- MRSN N/A
- EPS Growth
- LGI N/A
- MRSN N/A
- EPS
- LGI N/A
- MRSN N/A
- Revenue
- LGI N/A
- MRSN $34,837,000.00
- Revenue This Year
- LGI N/A
- MRSN N/A
- Revenue Next Year
- LGI N/A
- MRSN $7.15
- P/E Ratio
- LGI N/A
- MRSN N/A
- Revenue Growth
- LGI N/A
- MRSN N/A
- 52 Week Low
- LGI $12.66
- MRSN $1.22
- 52 Week High
- LGI $16.68
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- LGI 45.33
- MRSN 46.80
- Support Level
- LGI $16.31
- MRSN $1.98
- Resistance Level
- LGI $17.41
- MRSN $2.35
- Average True Range (ATR)
- LGI 0.25
- MRSN 0.28
- MACD
- LGI -0.01
- MRSN -0.04
- Stochastic Oscillator
- LGI 45.00
- MRSN 23.30
About LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt, and others.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.